Overview
Injectable B-complex is a compounded combination of water-soluble B vitamins typically supplied at 1–2 mL per dose for IM or SubQ injection, frequently used in IV-clinic settings, post-bariatric care, and self-injection community practice. Compositions vary by compounding pharmacy — the most common combination is thiamine (B1), riboflavin (B2), niacinamide (B3), pantothenic acid (B5), pyridoxine (B6), and methylcobalamin or cyanocobalamin (B12), with some adding biotin (B7) or folic acid/folate (B9). The clinical evidence is bimodal: where there is genuine deficiency in any of the constituents (Wernicke's encephalopathy, post-bariatric malabsorption, alcoholic patients), parenteral B-complex is essential and life-saving. In B-replete adults, the IV-clinic 'energy boost' marketing has no RCT support — the perceived benefit is largely placebo and saline-volume confounded.
Mechanism
Each component is a coenzyme/cofactor in core metabolism: thiamine (TPP) for pyruvate dehydrogenase and the pentose phosphate pathway; riboflavin (FAD/FMN) for the electron transport chain; niacin (NAD/NADP) for redox; pantothenic acid (CoA) for fatty-acid metabolism; pyridoxine (PLP) for amino-acid transamination and neurotransmitter synthesis; cobalamin (methyl/adenosyl) for methionine synthase and methylmalonyl-CoA mutase. Mechanistic logic for stacking these together is sound when intake is poor; mechanistic logic for stacking in replete adults is weak.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Wernicke's encephalopathy / acute thiamine deficiency
Parenteral thiamine (often given as part of B-complex or as IV thiamine) is standard of care for acute Wernicke's encephalopathy and alcohol-related thiamine deficiency. Decades of clinical evidence; this is among the most evidence-based parenteral interventions in modern medicine.
Post-bariatric / malabsorption B-vitamin maintenance
Standard of care for post-bariatric patients (especially Roux-en-Y, BPD/DS) is indefinite parenteral or high-dose oral B-vitamin supplementation due to predictable malabsorption. Tier 1 indication.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Generic deficiency from chronic alcoholism, severe malnutrition, hyperemesis gravidarum
Parenteral B-complex (or IV vitamin combos like banana bag) is standard inpatient practice for these populations. Decades of clinical evidence.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Adjunct in GLP-1 / metabolic peptide stacks (appetite-suppression-related undernutrition)
Metabolic peptides cause real reductions in food intake; some patients develop low-grade B-vitamin insufficiency. Supplementation makes preventive sense; the evidence base for the *combined* injectable form (vs targeted supplementation of measured deficits) is thinner.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
'Energy boost' / fatigue in B-replete adults
Heavy IV-clinic and 'B-12 / B-complex shot' marketing. No RCT supports B-complex supplementation in B-replete adults producing clinically meaningful energy or fatigue benefits. The perceived effect is dominated by saline-volume, B-vitamin renal-excretion ('expensive urine'), and clinic placebo.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Typical 1 mL injection volume of compounded B-complex contains a mix of mg-scale doses of each component (e.g., 100 mg B1, 2 mg B2, 100 mg B3, 2 mg B6, 1000 mcg B12). The mcg ranges shown apply to per-mL volumes for injection planning; component-level doses vary widely by formulation.
Contraindications
- Active hypersensitivity to any component (cobalt/cobalamin allergy, sulfite sensitivity)
- Pregnancy — most components are pregnancy-category-A/B individually, but high-dose B6 (>100 mg/day) has sensory neuropathy risk; check formulation
- Untreated severe B12 deficiency with megaloblastic anemia — folate alone or folate-heavy mixes can mask the diagnosis and accelerate neurologic damage; treat with B12 first or simultaneously
- Levodopa therapy (high-dose B6 reduces levodopa effectiveness — choose a B6-low formulation)
- Severe renal impairment (component clearance is renal; accumulation possible)
Reported side effects
- Injection-site pain, redness, swelling — IM more than SubQ; compounded B-complex preparations can sting because of preservatives and the niacin component
- Flushing (from niacin / niacinamide component)
- Bright yellow urine (from riboflavin — harmless, expected)
- Headache
- Mild nausea
- Sensory neuropathy with chronic high-dose B6 (>100 mg/day for months)
- Anaphylaxis (rare; usually attributed to thiamine or preservatives)
Reconstitution & storage
Most compounded injectable B-complex ships as a pre-mixed multi-dose vial (1–10 mL). No reconstitution needed for the most common preparations. Some pharmacies prepare lyophilized component vials that require reconstitution — follow pharmacy instructions. Always check that the compounded mixture is appropriate for the intended route — some preparations are IM-only.
Storage. Refrigerate 2–8 °C per label. Light-sensitive — keep in original carton. Some formulations are stable for 30–90 days post-opening; follow pharmacy-specific stability data.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. The library entry is intentionally honest about the bimodal evidence base — Tier 1 for actual deficiency, Tier 4 for 'energy boost' marketing in replete adults. Compounded B-complex formulations vary; the dose-range fields are necessarily approximate. Editorial line: name the formulation variability, name the IV-clinic placebo dynamics, refuse to soften the 'energy in replete adults' claim into anything stronger than Tier 4.
Citations
- [1]EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathyGalvin R, Bråthen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA · European Journal of Neurology · 2010 · PMID 20642653Foundational clinical guideline for parenteral thiamine in Wernicke's encephalopathy — anchor for Tier 1 deficiency indications.View source